5 things to try on a GLP-1: hype vs. what actually holds up

What did @maicyrobison actually say?

She offered five tips for breaking a weight loss plateau on GLP-1 medications: drink more water, manage stress better, switch your injection site, eat enough calories and fiber, and increase your movement intensity. The framing was practical and personal, drawing on her own experience injecting in her stomach before switching sites.

The tone was encouraging rather than alarmist, and she stayed away from dosing advice or miracle claims. She did repeat a common GLP-1 community belief that switching injection sites can restart weight loss, and she invoked "fight or flight mode" to explain what happens when you under-eat, which is a loose but not entirely wrong shorthand for metabolic adaptation. Overall, this reads like genuine community advice from someone living the experience, not a clinician reviewing evidence.

Does the science back this up?

Some of it holds up reasonably well. The rest ranges from plausible-but-unproven to outright oversimplified. Let's go claim by claim.

Hydration and weight retention is real physiology. When you are chronically under-hydrated, aldosterone and vasopressin promote fluid retention, which shows up on the scale. A 2019 paper by Thornton in the Journal of Physiology confirmed that even mild dehydration disrupts metabolic signaling. So the water advice is not just influencer noise.

Stress driving cortisol-mediated fat retention is also well-documented. Epel et al. (2000, Psychosomatic Medicine) showed cortisol reactivity correlated with abdominal fat accumulation. The suggestion to journal or meditate is soft but not wrong.

Under-eating triggering metabolic adaptation has strong support. Hall et al. (2016, Obesity) documented persistent metabolic rate suppression after caloric restriction. Describing this as "fight or flight" is reductive, but the practical message, eat enough protein and fiber to preserve metabolic rate, is sound.

The injection site claim is where the evidence gets thin. More on that below.

What did they get wrong (or right)?

The injection site switching tip is the weakest link here. The idea that moving from stomach to thigh to arm can "restart" weight loss is popular in GLP-1 communities, but the clinical evidence does not support it as a meaningful strategy for breaking plateaus. Semaglutide pharmacokinetics studies, including the manufacturer's own data reviewed by the FDA, show that subcutaneous absorption varies modestly by site but does not produce clinically significant differences in drug exposure for most patients. Rotating sites is recommended to prevent lipohypertrophy, not to boost efficacy. Presenting site-switching as a plateau-breaking tool is misleading, even if anecdotally people report feeling it helps.

On the other hand, she deserves credit for the under-eating point. Many GLP-1 users suppress appetite so aggressively that they drop below 800 calories a day, which is genuinely counterproductive for lean mass preservation and metabolic rate. Telling people to eat enough is not counterintuitive, it is actually underemphasized in most patient education.

The movement advice is generic but not wrong. Resistance training specifically has stronger evidence than step counts for preserving muscle during GLP-1-assisted weight loss, per Bilet et al. (2023, Obesity Reviews), but she did not make any specific errors here, just a soft recommendation.

What should you actually know?

Weight loss plateaus on GLP-1 medications are normal and expected. They are not automatically a sign that something is broken or that you need to change everything at once.

The most evidence-backed reasons for a stall include metabolic adaptation from inadequate protein intake, increased cortisol from sleep deprivation or chronic stress, and inaccurate calorie tracking. Drinking more water and moving more are reasonable baseline habits but are unlikely to break a true pharmacological plateau on their own.

If you have been on a stable GLP-1 dose for more than 12 weeks without progress, the conversation worth having is with your prescriber about dose titration or adjunct strategies, not about which thigh to inject into. Telehealth platforms with licensed clinical oversight exist precisely for this kind of structured follow-up. Crowd-sourced plateau tips from social media, even well-meaning ones, are not a substitute for that conversation.